US HB7473 | 2021-2022 | 117th Congress
Status
Spectrum: Partisan Bill (Democrat 8-0)
Status: Introduced on April 7 2022 - 25% progression, died in committee
Action: 2022-11-01 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Pending: House Subcommittee on Antitrust, Commercial, and Administrative Law Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on April 7 2022 - 25% progression, died in committee
Action: 2022-11-01 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Pending: House Subcommittee on Antitrust, Commercial, and Administrative Law Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To prohibit pharmaceutical manufacturers from interfering with therapeutically equivalent or interchangeable substitution decisions by health care providers to limit competition from a generic drug or biosimilar biological product, and for other purposes.
Title
Generic Substitution Noninterference Act
Sponsors
Rep. Carolyn Maloney [D-NY] | Rep. David Cicilline [D-RI] | Rep. Jerrold Nadler [D-NY] | Sen. Peter Welch [D-VT] |
Rep. Janice Schakowsky [D-IL] | Rep. Katie Porter [D-CA] | Rep. Mark DeSaulnier [D-CA] | Rep. Jamie Raskin [D-MD] |
History
Date | Chamber | Action |
---|---|---|
2022-11-01 | House | Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. |
2022-04-07 | House | Referred to the House Committee on the Judiciary. |
2022-04-07 | House | Introduced in House |
Subjects
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/117th-congress/house-bill/7473/all-info |
Text | https://www.congress.gov/117/bills/hr7473/BILLS-117hr7473ih.pdf |